How does Gilead Sciences make money?

GILEAD SCIENCES, INC. – Business Breakdown

The Essentials

Gilead Sciences is a biopharmaceutical company with a concentrated but strategically important footprint across HIV/AIDS, viral hepatitis, COVID-19, oncology, and other therapeutic areas. The filing set indicates a business model anchored in product sales, with HIV therapies forming the core earnings engine and oncology contributing a meaningful secondary growth vector. Its industrial significance derives from a portfolio of established branded therapies, a pipeline of next-generation assets, and a commercial base that is heavily weighted toward the U.S. market.

Business Model & Revenue Drivers

Gilead’s economic value is generated primarily through branded pharmaceutical product sales, with revenue concentration in a limited number of high-impact franchises.

• HIV franchise: The core revenue driver, with products such as Biktarvy, Genvoya, and Descovy identified as central to the company’s sales base. The profile specifically notes Biktarvy as a major contributor, with $3.15B in Q1 2025.
• Oncology portfolio: A growing but still secondary contributor, with approximately $757M in Q1 2025. Key products include Yescarta, Tecartus, and Trodelvy.
• Viral hepatitis / antiviral assets: Products such as Epclusa and Veklury remain part of the commercial mix, supporting diversification beyond HIV.
• Other products: The profile also references AmBisome as part of the broader revenue base.
• Geographic monetization: Revenue is predominantly U.S.-centric. In Q1 2025, the U.S. accounted for $4.631B of product sales and 70% of total product sales, while Europe contributed $1.073B and the Rest of World $909M.

Strategic Edge & Market Positioning

Gilead’s competitive position appears to rest on a combination of patent-protected assets, therapeutic differentiation, and commercial entrenchment rather than on structural cost leadership.

Economic Moat

• Patents and finite-lived intangibles: The profile highlights meaningful intellectual property protection, including sofosbuvir with a $2.3B net carrying value as of Dec. 31, 2025, and $2.4B of amortization expense in 2025. This indicates a material but time-limited protection layer.
• Switching costs in HIV: Single-tablet regimens such as Biktarvy and Genvoya create physician and patient inertia through efficacy, adherence convenience, and established reimbursement pathways.
• Portfolio depth in specialized therapies: The company’s presence in HIV, oncology, and antivirals supports a degree of franchise resilience.

Execution Advantage

• The profile does not evidence cost leadership, network effects, or other deeply structural barriers.
• Competitive positioning is described as dependent on efficacy, safety, and reimbursement, implying that execution quality and lifecycle management are critical.
• The moat is therefore best characterized as partial: patents and switching costs provide protection, but the durability of that protection is inherently finite and vulnerable to generic erosion after expiry.

Outlook & Innovation Pipeline

The next three years appear centered on pipeline conversion, label expansion, and franchise renewal across virology and oncology.

• Lenacapavir: A key HIV-1 capsid inhibitor with an NDA filed for yearly HIV PrEP and a Phase 3 oral combination program with bictegravir. This is one of the most strategically important assets in the pipeline.
• Trodelvy: The oncology platform remains active through sBLA filings, including combination development in NSCLC with pembrolizumab. However, the profile also notes a prior discontinuation of a Trodelvy NSCLC program, underscoring development risk.
• Bulevirtide: A major hepatitis delta virus asset with a BLA filed and Orphan/Breakthrough designations. It remains strategically relevant despite prior impairment activity.
• CAR-T expansion: The company is advancing cell therapy through Yescarta, Tecartus, and anitocabtagene autoleucel with Arcellx, for which a BLA has been filed in multiple myeloma.
• Collaborative R&D model: Gilead is leveraging partnerships with Arcus, Galapagos, Merck, and Janssen, indicating a capital-efficient approach to pipeline expansion and technology access.

Overall, the filing set suggests a company in transition: still highly dependent on HIV cash generation, but actively using that base to fund oncology, cell therapy, and next-generation antiviral innovation.